Moody's: No change to Abbott

Moody's Investors Service said its ratings on Abbott Laboratories are not affected by the company's agreement with US federal and state authorities to resolve an outstanding investigation of previous sales and marketing practices related to the neurological drug Depakote.

However, the agency said the development is credit negative because of the large $1.6 billion settlement amount and the acknowledged criminal violation of law.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.